Frontlight ResearchEarly access
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Key facts
- Who runs it
- Southeast University, China
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 36 people, planned
- Started
- 20 Feb 2026
- Expected to end
- 31 Jan 2027
- Type of study
- Interventional
- Treatments tested
- Thymalfasin
- Record updated
- 6 November 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Adults aged 18 to 85 years
- Admitted to the Department of Critical Care Medicine, Zhongda Hospital Southeast University, with sepsis diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3.0): confirmed or highly suspected infection with an acute increase in Sequential Organ Failure Assessment (SOFA) score of at least 2 points from baseline
- Written informed consent provided by the participant or legally authorized representative
Who cannot take part
- Previous solid organ or bone marrow transplantation
- Treatment within the past 30 days with immunosuppressive drugs (for example, tripterygium wilfordii, mycophenolate mofetil, cyclophosphamide, or tacrolimus) or continuous treatment with more than 10 mg/day prednisolone or an equivalent dose of another corticosteroid
- Use of thymosin drugs within the past 30 days or participation in another clinical study of a drug or device affecting immunity (for example, Xuebijing, ulinastatin, or continuous renal replacement therapy)
- Current or previous B-cell lymphoma, multiple myeloma, or leukemia
- Active connective tissue disease (for example, rheumatoid disease or systemic lupus erythematosus) or glomerulonephritis
- Current malignancy
- History of allergy or intolerance to thymalfasin
- Pregnancy or lactation
- Expected survival of less than 72 hours or a decision to receive restricted life-support treatment (comfort care only)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective, single-arm study will evaluate whether thymosin alpha 1 treatment affects serum immunoglobulin M (IgM) levels in adults with sepsis. Participants will receive standard care plus thymosin alpha 1 1.6 mg by subcutaneous injection every 12 hours for 5 days. Blood samples will be collected before treatment and on days 1, 3, 5, and 7 to measure IgM and plasma microvesicles. The study aims to clarify whether thymosin alpha 1 may support early immune responses in sepsis.
The group in the trial
- Thymosin alpha 1 treatment groupTreatment being tested
Adults with sepsis receiving standard clinical care plus thymosin alpha 1 1.6 mg subcutaneously every 12 hours for 5 days.
Treatment: Thymalfasin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Exploring the Correlation Between Thymosin Alpha 1 and IgM Levels in Sepsis Patients
- Record updated
- 6 November 2026